PBA
ONC

Paradigm Biocapital Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-347,787
Closed -$84.2M – 41
2025
Q2 		$84.2M Sell
347,787
-318,237
-48% -$78M 3.59% 7
2025
Q1 		$181M Buy
666,024
+50,000
+8% +$11.7M 8.3% 4
2024
Q4 		$114M Buy
616,024
+415,688
+207% +$84.9M 3.96% 9
2024
Q3 		$45M Buy
+200,336
New +$36M 1.52% 21
2023
Q3 		– Sell
-216,093
Closed -$38.5M – 36
2023
Q2 		$38.5M Buy
216,093
+32,081
+17% +$7.39M 2.98% 15
2023
Q1 		$39.7M Buy
+184,012
New +$44.1M 3.76% 13

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paradigm Biocapital Advisors's ONC Position: Q3 2025 in Review

Paradigm Biocapital Advisors sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 347,787 shares — an estimated $84.2M sold.

Paradigm Biocapital Advisors first reported a position in ONC in Q1 2023 and held it in 6 quarters. The position peaked at $181M in Q1 2025. 265 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • Paradigm Biocapital Advisors reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 347,787 BeOne Medicines Ltd shares in Q3 2025, an estimated $84.2M.
  • Paradigm Biocapital Advisors first reported a position in BeOne Medicines Ltd in Q1 2023 and held it in 6 quarters.
  • Paradigm Biocapital Advisors's BeOne Medicines Ltd position peaked at $181M in Q1 2025.
  • 265 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.